Enzon Pharmaceuticals Implements 1-for-100 Reverse Stock Split, Critical for Viskase Merger

summarizeSummary

Enzon Pharmaceuticals announced its 1-for-100 reverse stock split is effective today, March 24, 2026, a critical step required for the anticipated merger with Viskase Companies, Inc. and related exchange offer.

check_boxKey Events

• 1-for-100 Reverse Stock Split Effective

  The company's 1-for-100 reverse stock split became effective on March 24, 2026, at 4:30 p.m. ET. Common stock is expected to trade on a split-adjusted basis under the temporary symbol 'ENZND' starting March 25, 2026.

• Prerequisite for Viskase Merger

  The reverse stock split is a required step for the anticipated closing of the merger with Viskase Companies, Inc., and to facilitate the issuance of common stock in connection with the Series C Preferred Stock exchange offer.

• Rights Agreement Extended Again

  The Section 382 Rights Agreement was extended for the eleventh time, moving its final expiration date from March 24, 2026, to March 26, 2026, continuing a pattern of short-term extensions related to the ongoing corporate restructuring.

auto_awesomeAnalysis

Enzon Pharmaceuticals has officially implemented a 1-for-100 reverse stock split, a crucial step required for the completion of its anticipated transformational merger with Viskase Companies, Inc. This action, effective today, March 24, 2026, aims to make available authorized shares needed for the merger and a related exchange offer for Series C Preferred Stock. While reverse stock splits can be perceived negatively, in this context, it represents a necessary structural adjustment to facilitate a major corporate event for a company that reported significant net losses. Investors should monitor the progress of the Viskase merger and the exchange offer, as these are the primary drivers behind this corporate action.